EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer

Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, Wade Iams, Amanda Cass, Geoffrey Liu, Devalben Patel, Stephen V Liu, Gabriela Liliana Bravo Montenegro, Tejas Patil, Jorge J Nieva, Amanda Herrmann und 13 weitere

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70049 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Connor B Grady und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LUNGevity Foundation, Takeda Oncology, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Determining lines of therapy (LOT) using real‐world data is crucial to inform clinical decisions and support clinical research. Existing rules for determining LOT in patients with metastatic non‐small cell lung cancer (mNSCLC) do not incorporate the growing number of targeted therapies used in treatment today. Therefore, we propose rules for determining LOT from real‐world data of patients with mNSCLC treated with targeted therapies.

Methods

LOT rules were developed through expert consensus using a real‐world cohort of 550 patients with ALK + or ROS1 + mNSCLC in the multi‐institutional, electronic medical record‐based Academic Thoracic Oncology Medical Investigators Consortium's (ATOMIC) Driver Mutation Registry. Rules were subsequently modified based on a review of appropriate LOT determination. These resulting rules were then applied to an independent cohort of patients with EGFR + mNSCLC to illustrate their use.

Results

Six rules for determining LOTs were developed. Among 1133 patients with EGFR mutations and mNSCLC, a total of 3168 regimens were recorded with a median of 2 regimens per patient (IQR, 1–4; range, 1–13). After applying our rules, there were 2834 total LOTs with a median of 2 LOTs per patient (IQR, 1–3; range, 1–11). Rules 1–3 kept 11% of regimen changes from advancing the LOT. When compared to previously published rules, LOT assignments differed 5.7% of the time, mostly in LOTs with targeted therapy.

Conclusion

These rules provide an updated framework to evaluate current treatment patterns, accounting for the increased use of targeted therapies in patients with mNSCLC, and promote standardization of methods for determining LOT from real‐world data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationHumansMaleFemaleMiddle AgedAgedElectronic Health RecordsErbB ReceptorsRegistriesMolecular Targeted TherapyCohort StudiesAnaplastic Lymphoma Kinase

Stichwörter der Autor:innen

ALKEGFRROS1non‐small cell lung cancerreal‐world data

Substanzen

ErbB ReceptorsEGFR protein, humanAnaplastic Lymphoma Kinase

Autor:innen und Institutionen

  • Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, Georgetown University, Washington, DC, USA.
  • Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado, USA.
  • Department of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA.

Förderung

  • LUNGevity Foundation
  • Takeda Oncology
  • AstraZeneca

Zitieren

APA

Grady, C. B., Hwang, W. T., Reuss, J. E., Iams, W., Cass, A., Liu, G., Patel, D., Liu, S. V., Montenegro, G. L. B., Patil, T., Nieva, J. J., Herrmann, A., Marrone, K. A., Lam, V. K., Schwartzman, W., Dowell, J., Villaruz, L. C., Miller, K. L., Weiss, J., …, & Marmarelis, M. E. (2024). Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70049

Vancouver

Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, et al. Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70049

BibTeX
@article{Grady2024,
  author = {Grady, Connor B and Hwang, Wei-Ting and Reuss, Joshua E and Iams, Wade and Cass, Amanda and Liu, Geoffrey and Patel, Devalben and Liu, Stephen V and Montenegro, Gabriela Liliana Bravo and Patil, Tejas and Nieva, Jorge J and Herrmann, Amanda and Marrone, Kristen A and Lam, Vincent K and Schwartzman, William and Dowell, Jonathan and Villaruz, Liza C and Miller, Kelsey Leigh and Weiss, Jared and Sun, Fangdi and Velcheti, Vamsidhar and Camidge, D Ross and Aggarwal, Charu and Sun, Lova and Marmarelis, Melina E},
  title = {Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70049}
}
Kostenlos starten →